GLP-1 agonists vs Gastric Bypass Cost-Effectiveness GLP-1 agonists are not cost-effective compared to gastric bypass for patients with severe obesity if current drug pricing persists, with an incremental cost-effectiveness ratio exceeding $500,000 per QALY over 10 years
Key safety concerns identified in Phase 2 data include elevated resting heart rate, gastrointestinal side effects, increased hypoglycaemia risk when combined with insulin or sulfonylureas, and class-relevant cautions around pancreatitis and thyroid C-cell tumours
"Tirzepatide Once Weekly for the Treatment of Obesity." NEJM 2022 (SURMOUNT-1) ClinicalTrials.gov: TRIUMPH Phase 3 program trial protocols and status updates FDA Prescribing Information: Wegovy, Mounjaro/Zepbound, Saxenda (for comparative safety data) Frequently Asked Questions Most side effects peak during dose escalation (weeks 412) and improve substantially by week 24
Second, increased exposure to GLP-1RA, especially over extended durations, accentuated this protective association with a duration-response pattern
The best strategy is using the medication as a tool to build sustainable eating and training habits that can support maintenance even after stopping
While their review scores arent always as high as smaller competitors, you have to consider the sheer volume of them
